High-Dose Atorvastatin after Stroke or Transient Ischemic Attack
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Statins reduce the incidence of strokes among patients at increased risk for cardiovascular disease; whether they reduce the risk of stroke after a recent stroke or transient ischemic attack (TIA) remains to be established. METHODS: We randomly assigned 4731 patients who had had a stroke or TIA within one to six months before study entry, had low-density lipoprotein (LDL) cholesterol levels of 100 to 190 mg per deciliter (2.6 to 4.9 mmol per liter), and had no known coronary heart disease to double-blind treatment with 80 mg of atorvastatin per day or placebo. The primary end point was a first nonfatal or fatal stroke. RESULTS: The mean LDL cholesterol level during the trial was 73 mg per deciliter (1.9 mmol per liter) among patients receiving atorvastatin and 129 mg per deciliter (3.3 mmol per liter) among patients receiving placebo. During a median follow-up of 4.9 years, 265 patients (11.2 percent) receiving atorvastatin and 311 patients (13.1 percent) receiving placebo had a fatal or nonfatal stroke (5-year absolute reduction in risk, 2.2 percent; adjusted hazard ratio, 0.84; 95 percent confidence interval, 0.71 to 0.99; P=0.03; unadjusted P=0.05). The atorvastatin group had 218 ischemic strokes and 55 hemorrhagic strokes, whereas the placebo group had 274 ischemic strokes and 33 hemorrhagic strokes. The five-year absolute reduction in the risk of major cardiovascular events was 3.5 percent (hazard ratio, 0.80; 95 percent confidence interval, 0.69 to 0.92; P=0.002). The overall mortality rate was similar, with 216 deaths in the atorvastatin group and 211 deaths in the placebo group (P=0.98), as were the rates of serious adverse events. Elevated liver enzyme values were more common in patients taking atorvastatin. CONCLUSIONS: In patients with recent stroke or TIA and without known coronary heart disease, 80 mg of atorvastatin per day reduced the overall incidence of strokes and of cardiovascular events, despite a small increase in the incidence of hemorrhagic stroke. (ClinicalTrials.gov number, NCT00147602 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the recently published Lipitor's Effect in Alzheimer's Dementia (LEADe) trial, which included 640 randomized patients with mild Alzheimer disease, intensive lipid lowering by the addition of atorvastatin (80 mg) to donepezil did not improve cognitive function over a 72-week period.464”
In the citing paper
“Data from RCTs and meta-analyses indicate that routine early use of high-intensity statin therapy is associated with rapid and sustained clinical benefits [438-442].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [438]
In the citing paper
“Following stroke or TIA, 34 patients are at risk not only of recurrent cerebrovascular events but also of other major CV events including MI.”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [34]
In the citing paper
“Secondary prevention therapy with statins reduces the risk of recurrent stroke (by 12%), MI and vascular death.422,428”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [428]
In the citing paper
“Many reports have also indicated that there is no clear relationship between the TG level and cerebrovascular disease856, 862, 863).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [862]
Citations
Cites
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Sever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,782
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Cerebral Vascular Accidents in Patients over the Age of 60: II. Prognosis
Rankin, J. (1957) · Scottish Medical Journal · doi:10.1177/003693305700200504 · Cited by 2,506
Sacco, R. L., Adams, R., Albers, G., Alberts, M. J., Benavente, O., Furie, K., Goldstein, L. B., Gorelick, P., Halperin, J., Harbaugh, R., et al. (2006) · Stroke · doi:10.1161/01.str.0000199147.30016.74 · Cited by 1,873
Iso, H., Jacobs, D. R., Wentworth, D., Neaton, J. D., Cohen, J. D., & for the MRFIT Research Group* (1989) · New England Journal of Medicine · doi:10.1056/nejm198904063201405 · Cited by 1,133
Amarenco, P., Labreuche, J., Lavallée, P., & Touboul, P.-J. (2004) · Stroke · doi:10.1161/01.str.0000147965.52712.fa · Cited by 746
Research works printed but not linked: 1
- Waters DD, 2005, Circulation, 112, 2020
Cited by
Items 801–900 of 1,005
Navarese, E. P., Szczesniak, A. M., Kołodziejczak, M. M., Górny, B., Kubica, J., & Suryapranata, H. (2013) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-013-0053-0 · Cited by 38
Association of black race with recurrent stroke risk
Park, J., & Ovbiagele, B. (2016) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2016.04.012 · Cited by 32
Isabel, C., Calvet, D., & Mas, J. (2016) · La Presse Médicale · doi:10.1016/j.lpm.2016.10.009 · Cited by 42
Ringleb, P. A., Schellinger, P. D., & Hacke, W. (2008) · Der Nervenarzt · doi:10.1007/s00115-008-2531-1 · Cited by 43
Emerging agents for the treatment and prevention of stroke: progress in clinical trials
Safouris, A., Magoufis, G., & Tsivgoulis, G. K. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1985463 · Cited by 32
Improving Stroke Risk Factor Management Focusing on Health Disparities and Knowledge Gaps
Sur, N. B., Kozberg, M. G., Desvigne-Nickens, P. M., Silversides, C. K., Bushnell, C., Goldstein, L. B., Saver, J. L., Broderick, J. P., Gökçal, E., Merino, J. G., et al. (2023) · Stroke · doi:10.1161/strokeaha.122.040449 · Cited by 40
The Impact of Anti-Amyloid Immunotherapies on Stroke Care
Bilodeau, P., Dickson, J. R., & Kozberg, M. G. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051245 · Cited by 33
“However, a post-hoc analysis from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial demonstrated a higher risk of recurrent ICH in patients with a history of ICH who received atorvastatin [85].”
MethodStatins and Diabetes: The Good, the Bad, and the Unknown
Axsom, K., Berger, J. S., & Schwartzbard, A. Z. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0299-z · Cited by 34
Embolic complications after endovascular repair of abdominal aortic aneurysms
Toya, N., Baba, T., Kanaoka, Y., & Ohki, T. (2013) · Surgery Today · doi:10.1007/s00595-013-0795-y · Cited by 31
IGF-1 prevents simvastatin-induced myotoxicity in C2C12 myotubes
Bonifacio, A., Sanvee, G. M., Brecht, K., Kratschmar, D. V., Odermatt, A., Bouitbir, J., & Krähenbühl, S. (2016) · Archives of Toxicology · doi:10.1007/s00204-016-1871-z · Cited by 31
Khan, A., Akhtar, N., Kamran, S., Ponirakis, G., Petropoulos, I. N., Tunio, N. A., Dargham, S. R., Imam, Y. Z. B., Sartaj, F., Parray, A., et al. (2017) · Stroke · doi:10.1161/strokeaha.117.018289 · Cited by 32
Drug Therapy of Dyslipidemia in the Elderly
Yandrapalli, S., Gupta, S., Andries, G., Cooper, H. A., & Aronow, W. S. (2019) · Drugs & Aging · doi:10.1007/s40266-018-00632-x · Cited by 32
Cerebrovascular Disease and Statins
Beltrán, L. M., Vallejo‐Vaz, A. J., & Grijalvo, O. M. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.778740 · Cited by 33
Chobufo, M. D., Regner, S. R., Zeb, I., Lacoste, J. L., Virani, S. S., & Balla, S. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwac103 · Cited by 30
Gómez‐Hernández, A., Sánchez-Galán, E., Ortego, M., Martı́n-Ventura, J. L., Blanco‐Colio, L. M., Tarín, N., Jimenez-Nacher, J. J., López‐Bescós, L., Egido, J., & Tuñón, J. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.02.090 · Cited by 31
Pharmacotherapy for the Secondary Prevention of Stroke
Toyoda, Ḱ. (2009) · Drugs · doi:10.2165/00003495-200969060-00001 · Cited by 31
Jia, Z., Mohammed, W., Qiu, Y., Hong, X., & Shi, H. (2013) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2012.12.016 · Cited by 31
Mok, V., Lam, W. W. M., Chen, X. Y., Wong, A., Ng, P. W., Tsoi, T. H., Yeung, V., Liu, R., Soo, Y. O. Y., Leung, T. W. H., et al. (2009) · Cerebrovascular Diseases · doi:10.1159/000215939 · Cited by 35
Serum lipid profile on admission for ischemic stroke
Smith, E. E., Abdullah, A. R., Amirfarzan, H., & Schwamm, L. H. (2007) · Neurology · doi:10.1212/01.wnl.0000255941.03761.dc · Cited by 30
Sakamoto, T., & Ogawa, H. (2010) · Circulation Journal · doi:10.1253/circj.cj-10-0537 · Cited by 31
Prise en charge des accidents vasculaires cérébraux en Afrique subsaharienne
Adoukonou, T., Vallat, J., Joubert, L., Macian, F., Kaboré, R., Magy, L., Houinato, D. S., & Preux, P. (2010) · Revue Neurologique · doi:10.1016/j.neurol.2010.06.004 · Cited by 35
Vegter, S., Oosterhof, P., van Boven, J. F. M., Stuurman-Bieze, A. G. G., Hiddink, E., & Postma, M. J. (2014) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2014.20.7.722 · Cited by 40
Amarenco, P., & Steg, P. G. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn232 · Cited by 34
Diabetes mellitus and cerebrovascular disease: which are the actual data?
Hatzitolios, A., Didangelos, T., Zantidis, A., Tziomalos, K., Giannakoulas, G., & Karamitsos, D. (2009) · Journal of diabetes and its complications · doi:10.1016/j.jdiacomp.2008.01.004 · Cited by 40
Mok, T. (2010) · The HKU Scholars Hub (University of Hong Kong) · Cited by 31
Montelione, N., Loreni, F., Nenna, A., Catanese, V., Scurto, L., Ferrisi, C., Jawabra, M., Gabellini, T., Codispoti, F. A., Spinelli, F., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11030798 · Cited by 30
“In the atorvastatin group, these effects were balanced by a small but significant increase in hemorrhagic stroke risk, compared to placebo [93].”
BackgroundYang, J., Shi, X., Wang, Y., Ma, M., Liu, H., Wang, J., & Xu, Z. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230593 · Cited by 34
Recent advances in the prevention of secondary ischemic stroke: A narrative review
Qiao, Y., Fayyaz, A. I., Ding, Y., Ji, X., & Zhao, W. (2024) · Brain Circulation · doi:10.4103/bc.bc_159_24 · Cited by 39
“[62] In recent years, numerous studies have demonstrated that achieving lower low-density lipoprotein cholesterol (LDL-C) levels is associated with reduced risk of recurrent stroke.”
Statins and clinical outcome of acute ischemic stroke: a systematic review
Lakhan, S. E., Bagchi, S., & Hofer, M. (2010) · International Archives of Medicine · doi:10.1186/1755-7682-3-22 · Cited by 33
Antithrombotic Therapy in Carotid Artery Stenosis: An Update
Paciaroni, M., & Bogousslavsky, J. (2014) · European Neurology · doi:10.1159/000367988 · Cited by 32
Schernthaner, G.-H. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02025.x · Cited by 34
Nishiyama, Y., Ueda, M., Otsuka, T., Katsura, K., Abe, A., Nagayama, H., & Katayama, Y. (2011) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.5553 · Cited by 33
Is There a Place for Cerebral Preconditioning in the Clinic?
Keep, R. F., Wang, M. M., Xiang, J., Hua, Y., & Xi, G. (2010) · Translational Stroke Research · doi:10.1007/s12975-009-0007-7 · Cited by 30
Saito, T., Nito, C., Ueda, M., Inaba, T., Kamiya, F., Muraga, K., Katsura, K., & Katayama, Y. (2013) · Life Sciences · doi:10.1016/j.lfs.2013.11.018 · Cited by 32
Fuentes, B., Gállego, J., Gil-Núñez, A., Morales, A., Purroy, F. F., Roquer, J., Segura, T., Tejada, J., Lago, A. P., Díez‐Tejedor, E., et al. (2012) · Neurología (English Edition) · doi:10.1016/j.nrleng.2011.06.004 · Cited by 49
Ischemic stroke in young adults
Stack, C. A., & Cole, J. W. (2018) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000564 · Cited by 31
Number needed to treat: A primer for neurointerventionalists
Martínez-Gutiérrez, J. C., Leslie‐Mazwi, T. M., Chandra, R. V., Ong, K. L., Nogueira, R. G., Goyal, M., Albuquerque, F. C., & Hirsch, J. A. (2019) · Interventional Neuroradiology · doi:10.1177/1591019919858733 · Cited by 34
Statin therapy in acute cardioembolic stroke with no guidance-based indication
Park, H., Lee, J. S., Hong, K., Cho, Y., Park, J., Kang, K., Lee, S. J., Kim, J. G., Cha, J., Kim, D., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000009397 · Cited by 31
“High-intensity statin therapy may reduce stroke recurrence and cardiovascular events in patients with recent ischemic stroke or TIA and no known coronary heart disease (CHD).(1) Current stroke guidelines recommend statin therapy for patients with ischemic stroke or TIA of presumed atherosclerotic origin.”
BackgroundDyslipidemia and prevention of atherosclerotic cardiovascular disease in the elderly
LUCCHI, T. (2022) · Minerva Medica · doi:10.23736/s0026-4806.21.07347-x · Cited by 41
Vitamin D as therapeutic modulator in cerebrovascular diseases: a mechanistic perspectives
Rihal, V., Khan, H., Kaur, A., & Singh, T. G. (2022) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2022.2050349 · Cited by 36
Mayerhofer, E., Malik, R., Parodi, L., Burgess, S., Harloff, A., Dichgans, M., Rosand, J. M., Anderson, C. D., & Georgakis, M. K. (2022) · Brain · doi:10.1093/brain/awac186 · Cited by 31
Drug Eluting Stents for Symptomatic Intracranial and Vertebral Artery Stenosis
Fields, J. D., Petersen, B. D., Lutsep, H. L., Nesbit, G. M., Liu, K. C., Doğan, A. F., Lee, D. S., Clark, W. M., & Barnwell, S. L. (2011) · Interventional Neuroradiology · doi:10.1177/159101991101700217 · Cited by 30
Statins in Ischemic Stroke: Just Low-Density Lipoprotein Lowering or More?
Ganti, L., Vaidyanathan, L., Kumar, G., Bellolio, F., Brown, R. D., Suravaram, S., Enduri, S., Gilmore, R. M., & Decker, W. W. (2009) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2008.09.016 · Cited by 33
Lipid Profile Components and Subclinical Cerebrovascular Disease in the Northern Manhattan Study
Willey, J. Z., Gardener, H. E., Moon, Y. P., Yoshita, M., DeCarli, C. S., Cheung, Y. K., Sacco, R. L., Elkind, M. S. V., & Wright, C. B. (2014) · Cerebrovascular Diseases · doi:10.1159/000362920 · Cited by 34
Treatment Targets in Intracerebral Hemorrhage
Sangha, N. S., & Gonzales, N. R. (2011) · Neurotherapeutics · doi:10.1007/s13311-011-0055-z · Cited by 33
Intracranial Atherosclerotic Disease
Khan, M., Naqvi, I. A., Bansari, A., & Kamal, A. K. (2011) · Stroke Research and Treatment · doi:10.4061/2011/282845 · Cited by 32
Wang, B., Zhao, H., Li, Z., Dai, X., Wang, D., Cao, J., & Niu, W. (2008) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2008.09.013 · Cited by 31
Lee, S., Chu, K., Park, J., Hong, N. H., Im, W., Kang, L., Han, Z., Jung, K., Kim, M., & Kim, M. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05044.x · Cited by 37
“Experimentally, atorvastatin has been used at 10 mg/kg to achieve a maximal neuroprotective effect (Laufs et al. 2000), and clinically, atorvastatin is well tolerated at up to 80 mg/day (Amarenco et al. 2006).”
MethodClinical Neuroprotective Drugs for Treatment and Prevention of Stroke
Kikuchi, K., Uchikado, H., Morioka, M., Murai, Y., & Tanaka, E. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13067739 · Cited by 30
Secondary prevention of stroke
MacDougall, N., Amarasinghe, S., & Muir, K. W. (2009) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.09.77 · Cited by 35
Sjölander, M., Eriksson, M., & Glader, E. (2016) · European Stroke Journal · doi:10.1177/2396987316646026 · Cited by 32
National Stroke Audit: The Australian experience
Cadilhac, D. A.-M., & Harris (2010) · Clinical Audit · doi:10.2147/ca.s9435 · Cited by 30
Dregan, A., van Staa, T. P., McDermott, L. M., McCann, G., Ashworth, M. J., Charlton, J., Wolfe, C. D. A., Rudd, A. G., Yardley, L., Gulliford, M. C., et al. (2014) · Stroke · doi:10.1161/strokeaha.114.005713 · Cited by 33
Health Promotion Integrated Into a Thai PharmD Curriculum to Improve Pharmacy Practice Skills
Sookaneknun, P., Suttajit, S., Ploylearmsang, C., Kanjanasilp, J., & Maleewong, U. (2009) · American Journal of Pharmaceutical Education · doi:10.1016/s0002-9459(24)00132-3 · Cited by 30
Inpatient Management of Acute Stroke of Unknown Type in Resource-Limited Settings
Prust, M., Saylor, D. R., Zimba, S., Sarfo, F. S., Shrestha, G. S., Berkowitz, A., & Vora, N. (2022) · Stroke · doi:10.1161/strokeaha.121.037297 · Cited by 31
Preexisting Statin Use Is Associated With Greater Reperfusion in Hyperacute Ischemic Stroke
Ford, A. L., An, H., D’Angelo, G., Ponisio, R., Bushard, P. J., Vo, K. D., Powers, W. J., Lin, W., & Lee, J. (2011) · Stroke · doi:10.1161/strokeaha.110.600957 · Cited by 30
Shin, J., Chung, J., Jang, H.-S., Lee, J., Hong, K., Bang, O. Y., Kim, G., & Seo, W. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319830503 · Cited by 33
Stampfer, H. G., Gabb, G. M., & Dimmitt, S. B. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14032 · Cited by 33
Teoh, R., Huang, C., Chan, C. P., Chien, L., Chung, C., Sung, S., Chen, C.-H., Chiang, C., & Cheng, H. (2019) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286419864830 · Cited by 33
The Prevention of Cardiovascular Disease in Older Adults
Coll, P. P., Roche, V., Olsen, J. S., Voit, J. H., Bowen, E., & Kumar, M. (2020) · Journal of the American Geriatrics Society · doi:10.1111/jgs.16353 · Cited by 36
“There is strong evidence that patients who have had a stroke or a TIA benefit from the use of lipid-lowering agents to reduce the risk of a future stroke.(34) Older adults with a history of stoke or TIA also benefit from the use of lipid-lowering agents.”
BackgroundSafety of Statins and Nonstatins for Treatment of Dyslipidemia
Newman, C. B. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.01.004 · Cited by 39
Ictus. Diagnóstico y tratamiento de las enfermedades cerebrovasculares
Ustrell, X., & Serena, J. L. (2007) · Revista Española de Cardiología · doi:10.1157/13108281 · Cited by 105
Plosker, G. L., & Lyseng-Williamson, K. A. (2007) · PharmacoEconomics · doi:10.2165/00019053-200725120-00005 · Cited by 40
Secondary Prevention after Minor Stroke and TIA - Usual Care and Development of a Support Program
Leistner, S., Benik, S., Laumeier, I., Ziegler, A. M., Nieweler, G., Nolte, C. H., Heuschmann, P. U., & Audebert, H. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049985 · Cited by 33
Miller, A., Hansen, L., & Saseen, J. J. (2008) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.5.553 · Cited by 29
Statin–Drug Interactions: Not a Class Effect
Frishman, W. H., & Horn, J. R. (2008) · Cardiology in Review · doi:10.1097/crd.0b013e31817532db · Cited by 34
Influence of stroke subtype on quality of care in the Get With The Guidelines–Stroke Program
Smith, E. E., Liang, L., Hernandez, A. F., Reeves, M. J., Cannon, C. P., Fonarow, G. C., & Schwamm, L. H. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b59a6e · Cited by 32
Béjot, Y., Zeller, M., Lorgis, L., Troisgros, O., Aboa-Éboulé, C., Osseby, G., Giroud, M., & Cottin, Y. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-303267 · Cited by 29
Yang, J., Pan, Y., Li, X., & Wang, X. (2015) · Brain Research · doi:10.1016/j.brainres.2015.10.032 · Cited by 31
Shah, N. S., Huffman, M. D., Ning, H., & Lloyd‐Jones, D. M. (2013) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.113.000112 · Cited by 29
Wada, S., Koga, M., Toyoda, Ḱ., Minematsu, K., Yasaka, M., Nagai, Y., Aoki, S., Nezu, T., Hosomi, N., Kagimura, T., et al. (2017) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.41533 · Cited by 32
Trends in stroke subtypes and vascular risk factors in a stroke center in China over 10 years
Tian, D., Yang, Q., Dong, Q. S., Li, N., Yan, B., & Fan, D. (2018) · Scientific Reports · doi:10.1038/s41598-018-23356-9 · Cited by 32
Association Between Statin Use and Uveitis: Results From the Pacific Ocular Inflammation Study
Borkar, D. S., Tham, V. M., Shen, E. P., Parker, J. V., Uchida, A., Vinoya, A. C., & Acharya, N. R. (2015) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2015.01.009 · Cited by 29
Bybee, K. A., Lee, J., & O’Keefe, J. H. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x292001 · Cited by 31
Leistner, S., Michelson, G., Laumeier, I., Ahmadi, M., Smyth, M., Nieweler, G., Doehner, W., Sobesky, J., Fiebach, J. B., Marx, P., et al. (2013) · BMC Neurology · doi:10.1186/1471-2377-13-11 · Cited by 31
Statins for Secondary Prevention of Cardiovascular Disease: The Right Dose
Spector, R., & Snapinn, S. M. (2011) · Pharmacology · doi:10.1159/000322999 · Cited by 32
Exploring new indications for statins beyond atherosclerosis: Successes and setbacks
Waters, D. D. (2010) · Journal of Cardiology · doi:10.1016/j.jjcc.2009.12.003 · Cited by 33
Blood lipid levels, statin therapy and the risk of intracerebral hemorrhage
Ma, Y., Li, Z., Chen, L., & Li, X. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0213-8 · Cited by 35
Cryptogenic Stroke and Nonstenosing Intracranial Calcified Atherosclerosis
Kamel, H., Gialdini, G., Baradaran, H., Giambrone, A. E., Navi, B. B., Lerario, M. P., Min, J. K., Iadecola, C., & Gupta, A. K. (2016) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2016.10.035 · Cited by 28
Kim, B. J., Kang, H. G., Lee, S.-W., Jung, J., Lee, M.-H., Kang, D., Kim, J. S., & Kwon, S. U. (2018) · Journal of Clinical Neurology · doi:10.3988/jcn.2018.14.1.35 · Cited by 28
Heldner, M. R., Li, L., Lovett, N. G., Kubiak, M. M., Lyons, S., Rothwell, P. M., & Study, F. T. O. V. (2018) · Stroke · doi:10.1161/strokeaha.118.020913 · Cited by 29
Laleman, N., Henrard, S., van den Akker, M., Goderis, G., Buntinx, F., Pottelbergh, G. V., & Vaes, B. (2018) · BMC Cardiovascular Disorders · doi:10.1186/s12872-018-0941-y · Cited by 31
Furtado, R. H. M., & Giugliano, R. P. (2020) · Cardiology and Therapy · doi:10.1007/s40119-020-00163-w · Cited by 34
Current Status of Dyslipidemia Treatment for Stroke Prevention
Aradine, E., Hou, Y., Cronin, C. A., & Chaturvedi, S. (2020) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-020-01052-4 · Cited by 28
Prevalence, prognosis, and treatment of atherosclerotic intracranial stenosis in Caucasians
Hurford, R., & Rothwell, P. M. (2020) · International Journal of Stroke · doi:10.1177/1747493020974461 · Cited by 31
“Management of the primary risk factors for atherosclerosis (elevated blood pressure, poor glycemic control, and elevated low-density lipoprotein (LDL) cholesterol) has been shown to be effective secondary prevention of ischemic stroke of any etiology.(76,77) Evidence in patients with symptomatic ICS is derived indirec…”
BackgroundFive‐Year Risk of Acute Myocardial Infarction After Acute Ischemic Stroke in Korea
Lee, K., Kim, S., Kim, J. Y., Kang, J., Kim, B. J., Han, M., Choi, K., Kim, J., Shin, D., Cha, J., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.018807 · Cited by 30
Self-citationStroke Risk Factors of Stroke Patients in China: A Nationwide Community-Based Cross-Sectional Study
Chen, J., Zhu, Q., Yu, L., Li, Y., Jia, S., & Zhang, J. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19084807 · Cited by 32
Pitavastatin Strengthens the Barrier Integrity in Primary Cultures of Rat Brain Endothelial Cells
Morofuji, Y., Nakagawa, S., So, G., Hiu, T., Horai, S., Hayashi, K., Tanaka, K., Suyama, K., Deli, M. A., Nagata, I., et al. (2010) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-010-9497-9 · Cited by 28
“There is clinical evidence revealed that statins have a beneficial, pleiotropic effect of stroke prevention on cerebrovascular diseases (Amarenco et al. 2006; Nassief and Marsh 2008).”
BackgroundVenketasubramanian, N., Röther, J., Bhatt, D. L., Pasquet, B., Mas, J., Alberts, M. J., Hill, M. D., Aichner, F., Steg, P. G., & REACH Investigators (2011) · Cerebrovascular Diseases · doi:10.1159/000328650 · Cited by 30
Carotid Artery Stent Placement
White, C. J. (2010) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2010.04.002 · Cited by 28
Simon, R. W., van der Loo, B., Kovacevic, T., Brockes, C., Rousson, V., Amann-Vesti, B. R., Spring, S., & Koppensteiner, R. (2007) · Thrombosis and Haemostasis · doi:10.1160/th07-04-0265 · Cited by 30
“Furthermore, intense statin therapy has been shown to have an effect both in the primary (2) and secondary prevention of stroke (3).”
BackgroundEggertsen, R., Andreasson, Å., & Andrén, L. (2007) · Scandinavian Journal of Primary Health Care · doi:10.1080/02813430701442768 · Cited by 29
The Atorvastatin During Ischemic Stroke Study: A Pilot Randomized Controlled Trial
Muscari, A., Puddu, G. M., Santoro, N., Serafini, C., Cenni, A., Rossi, V. A., & Zoli, M. (2011) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3182206c2f · Cited by 29
Campbell, B. C. V. (2019) · The Medical Journal of Australia · doi:10.5694/mja2.50137 · Cited by 31
Therapeutic strategy for atherosclerosis based on bone-vascular axis hypothesis
Kim, J., Lee, W. S., & Kim, J. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107436 · Cited by 29
Stroke — An Equal Opportunity for the Initiation of Statin Therapy
Kent, D. M. (2006) · New England Journal of Medicine · doi:10.1056/nejme068146 · Cited by 29
STATIN TREATMENT WITHDRAWAL IN ISCHEMIC STROKE: A CONTROLLED RANDOMIZED STUDY
Mascitelli, L., & Pezzetta, F. (2008) · Neurology · doi:10.1212/01.wnl.0000313836.85138.40 · Cited by 28
Ueno, Y., Yamashiro, K., Tanaka, Y., Watanabe, M., Miyamoto, N., Shimada, Y., Kuroki, T., Tanaka, R., Miyauchi, K., Daida, H., et al. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.02.021 · Cited by 30
Clinical evidence of statin therapy in non-dyslipidemic disorders
Ferri, N., & Corsini, A. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.02.003 · Cited by 31
Khan, A., Kamran, S., Akhtar, N., Ponirakis, G., Almuhannadi, H., Petropoulos, I. N., Al-Fahdawi, S., Qahwaji, R., Sartaj, F., Babu, B. M., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-35298-3 · Cited by 29
Metadata
- Authors
- The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators
- Affiliations
- Université Paris Diderot (FR)
- Corresponding author
- The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-08-10
- Volume
- 355
- Issue
- 6
- Pages
- 549-559
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1546258268
- Cited by
- 2,887
- References
- 21
- Citations by year
- 2026: 86 · 2025: 96 · 2024: 119 · 2023: 112 · 2022: 135 · 2021: 134 · 2020: 139 · 2019: 140 · 2018: 129 · 2017: 132 · 2016: 139 · 2015: 125 · 2014: 142 · 2013: 160 · 2012: 149
- FWCI
- 200.93
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Eisai
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cerebrovascular and Carotid Artery Diseases
- Keywords
- atorvastatin, high-intensity statin therapy, stroke, transient ischemic attack, secondary stroke prevention, LDL cholesterol lowering, hemorrhagic stroke, ischemic stroke, cardiovascular events, elevated liver enzymes, lipid-lowering therapy, mortality, serious adverse events
- MeSH terms
- Atorvastatin, Adult, Cardiovascular Diseases, Cerebral Hemorrhage, Cerebral Infarction, Ischemic Attack, Transient, Drug Therapy, Combination, Female, Heptanoic Acids, Humans, Cholesterol, LDL, Male, Pyrroles, Risk, Proportional Hazards Models, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Stroke, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.